NCT04652466

Brief Summary

For nearly half a century, supraglottic airway devices (SGA) have been used in pediatric patients, which are more practical than face masks, facilitate oxygenation and ventilation without the need for endotracheal intubation, and less invasive than endotracheal tubes. I-Gel is a supraglottic airway management device introduced in 2007, made of a medical grade thermoplastic elastomer, designed to create a non-inflatable, anatomical seal in the pharyngeal, laryngeal and perilaryngeal structures that prevents compression trauma. Recently, the use of I-Gel has become popular in children undergoing surgery that does not require muscle relaxation. It is important to place an I-Gel in the most appropriate position in order to provide adequate ventilation and prevent complications such as mucosal injury, glottic ptosis, and gastric insufflation with potential aspiration. Successful placement is usually clinically assessed by a capnogram with endtidal carbon dioxide (ETCO2) value, visual examination and auscultation with appropriate chest elevation, absence of oropharyngeal leakage at 20 cm H2O peak inspiratory pressure. Although Fiberoptic Bronchoscope (FOB) is accepted as the preferred verification tool for direct visualization, some studies on I-Gel position using FOB reported that I-Gel placement should be repositioned in some children (12.8-49%). Ultrasonography (USG), which has recently entered the practice of upper airway examination, has become a valuable, non-invasive, simple and portable technology for evaluating airway management even in upper airway anatomy impaired by pathology or trauma. The aim of this study is to compare the use of USG with the FOB to evaluate I-Gel placement in pediatric patients. The primary endpoint is to compare the incidence of for I-Gel malposition between USG and FOB. Secondary endpoints are to find the correlation between I-Gel's USG and FOB-detected malposition and to determine the diagnostic performance of the USG.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 26, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

December 3, 2020

Completed
12 days until next milestone

Study Start

First participant enrolled

December 15, 2020

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2021

Completed
16 days until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2021

Completed
Last Updated

December 3, 2020

Status Verified

November 1, 2020

Enrollment Period

2 months

First QC Date

November 26, 2020

Last Update Submit

November 26, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • the incidence of for I-Gel malposition between USG and FOB

    to compare the incidence of for I-Gel malposition between USG and FOB.

    1 months

Secondary Outcomes (1)

  • the correlation between I-Gel's USG and FOB

    1 months

Interventions

To compare the incidence of for I-Gel malposition between USG and FOB, and to find the correlation between I-Gel's USG and FOB-detected malposition

Eligibility Criteria

Age1 Month - 6 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

The pediatric patients who were scheduled to undergo surgery under general anesthesia placed I-Gel for airway were enrolled in the study.

You may qualify if:

  • Undergoing elective pediatric surgery
  • American Society of Anesthesiologists (ASA) status I-II
  • Placed I-Gel for airway

You may not qualify if:

  • Patients with head and neck anatomical malformation and airway congenital defects

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Selcuk University, School of Medicine

Konya, 42250, Turkey (Türkiye)

Location

Study Officials

  • Faruk Cicekci

    Selcuk University, School of Medicine, Department of Anesthesiology and Intensive Care

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

November 26, 2020

First Posted

December 3, 2020

Study Start

December 15, 2020

Primary Completion

January 30, 2021

Study Completion

February 15, 2021

Last Updated

December 3, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations